All Oncology News

Treatment with the tyrosine kinase inhibitor neratinib demonstrated a 2-year disease-free survival rate of 93.9% in patients with early-stage HER2-positive breast cancer, representing a 33% improvement compared with placebo.

Treating patients with chemorefractory advanced colorectal cancer has undergone a significant transformation in recent years. Now, with two agents approved, the optimal sequence for therapies regorafenib and TAS-102 becomes the next relevant question.

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen.

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

Howard L. Kaufman, MD, discusses remaining questions regarding T-VEC, the impact of the FDA approval, and its future potential.

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

Robert Ferris, MD, PhD, discusses CheckMate-141, the biggest remaining challenges in head and neck cancer, and the potential for nivolumab as a treatment of patients with the disease.

Management of hepatic malignancies requires a multidisciplinary approach, and is based on the tumor burden, liver function, and PS of the patient.

Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.

The phase III TOWER study has been halted after an independent panel determined that blinatumomab (Blincyto) improved overall survival versus standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The FDA approved single-dose fosaprepitant dimeglumine (Emend for injection) in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC), according to Merck, the developer of the drug.

With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.

ASCO has named immunotherapy, targeting agents that block PD-1/PD-L1 immune checkpoint across a vast array of tumor types, as its “Cancer Advance of the Year.”

Philippe Moreau, MD, discusses the significance of ixazomib and the TOURMALINE-MM1 study, as well as the benefit of an oral regimen for the treatment of patients with relapsed multiple myeloma.

The European Commission has granted a conditional marketing authorization to osimertinib for patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with EGFR TKI.

The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.

Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers caused by a gene mutated in several types of brain tumors.

Study identifies a potential drug target for inhibiting common radiation-induced fibrosis.

New study shows blood test does better job than current standard test at tracking severity and potential spread of metastatic melanoma.

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years following surgery.

NYU Langone Medical Center first in Northeast to utilize new technology allowing surgeons to destroy only suspicious prostate tissue.

E. David Crawford, MD, discusses his view of the current role for PSA testing in prostate cancer and the need for continued innovation and advancement with new screening technologies.

Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine in the first-line setting.

Combining nivolumab (Opdivo) with radiation therapy may provide better disease control and prolong overall survival in patients with melanoma whose disease has metastasized to the brain, compared with standard current treatment.

Jedd D. Wolchok, MD, discusses the implications of the expanded FDA approval of nivolumab, and the potential for the PD-1 inhibitor as both a single agent and as part of a combination regimen in advanced melanoma

The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival with cabozantinib (Cometriq) versus everolimus as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Leonard G. Gomella, MD, discusses intermittent hormonal therapy for patients with prostate cancer as well as its benefits and challenges.

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.